PI: Alan Barker, MD

PACCM is a nationally-recognized Clinical Resource Center through the Alpha-1 Foundation and participates in the Therapeutic Development Network (TDN).

ELEVAATE-OLE: Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency Emphysema NCT05897424

PI: Shyam Joshi, MD

No active trials at this time

PI: Alan Barker, MD

博彩网站 participates in the Bronchiectasis Research Registry, led by the COPD Foundation.

PI: Daniel Seifer, MD

ALOFT-IPF: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis NCT06003426

ALOFT-PPF: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis NCT06025578

PI: Alan Barker, MD

MIDAS: Multicenter International Durability and Safety of Sirolimus in LAM

LAM Foundation

PI: Jeffrey Robinson, MD

SOTERIA: An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH NCT04796337

PROSERA: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH) NCT05934526

ADVANCE Outcomes: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ralinepag when Added to Pulmonary Arterial Hypertension (PAH) Standard of Care or PAH-Specific Background Oral Therapy in Subjects with World Health Organization (WHO) Group 1 Pulmonary Hypertension NCT03626688 

UNISUS: A Phase 3, Prospective, Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel-Group, Group-Sequential, Adaptive, Event-Driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75mg vs. Macitentan 10mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-Label Treatment Period with Macitentan 75mg NCT04273945

DECIPHER-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) NCT06388421

PI: Julianna Desmarais, MD

CONQUEST: Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis NCT06195072